Financial Data and Key Metrics Changes - Revenue for Q4 2022 was $139 million, a 10% increase year-over-year and an 8% sequential increase, marking the fourth consecutive quarter of sequential growth [7] - For the full year 2022, revenue was $510 million, a 5% increase compared to the previous year [18] - GAAP gross margin was 41%, while adjusted gross margin improved to 44.5%, a 460 basis point increase year-over-year [11] - Adjusted EBITDA loss for the full year was $48 million, with expectations for adjusted EBITDA growth to exceed revenue growth in 2023 [18][48] Business Line Data and Key Metrics Changes - Clinical Services and Pharma Services both contributed to revenue growth, with Pharma Services showing a 41% revenue increase in Q4 compared to the prior year [19] - RaDaR for Pharma experienced over 300% growth year-over-year in Q4, highlighting strong demand and performance [10] - Adjusted gross profit for the full year was $207 million, representing an adjusted gross margin of 41% [18] Market Data and Key Metrics Changes - The company served over 625,000 patients and processed over 1 million test orders in 2022, indicating strong market presence [18] - Days Sales Outstanding (DSO) improved to 79.4 days by the end of the year, reflecting better cash flow management [23] Company Strategy and Development Direction - The company initiated an organizational restructuring, including the integration of the Inivata business, expected to yield approximately $25 million in annualized operating savings [8] - A renewed focus on NGS MRD technologies, including RaDaR and Neo Comprehensive, is aimed at maintaining leadership in the oncology market [26] - The company plans to optimize its field organization and expand its oncology sales force to enhance customer experience and operational efficiency [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing revenue growth and operational improvements into 2023, with a revenue guidance of $545 million to $555 million, representing 7% to 9% growth [47] - The management team emphasized the importance of sustainable long-term growth rather than short-term earnings, indicating a strategic focus on reinvestment for future profitability [73] - Management acknowledged past market share losses but noted recovery efforts through field expansion and improved sales strategies [36] Other Important Information - The company is focusing on operational efficiencies and has integrated its R&D functions to capitalize on innovation opportunities [51] - The Advanced Diagnostics division is expected to drive significant growth through new product launches and a comprehensive data strategy [52] Q&A Session Summary Question: What are the growth expectations for NGS and turnaround times? - Management indicated strong growth in NGS and a competitive turnaround time of 10 days for the new Neo Comprehensive offering, with ongoing improvements expected [93] Question: How does the company view the Pharma Services market? - Management noted that while there are macro headwinds, they believe their strong relationships and focus on earlier-stage studies will drive continued growth in Pharma Services [144][149] Question: What is the outlook for RaDaR and its reimbursement strategy? - Management confirmed plans to submit for reimbursement for breast cancer in the first half of the year and colorectal cancer in the second half, emphasizing the importance of strong data for approval [142][163]

Sequential Improvement in Revenue Growth, • Adjusted EBITDA. Improved $8.6 million versus prior year due to improvement in gross profit and lower operating expenses. Balance Sheet In $Millions Dec-22 Sep-22 Total Assets 1,740.0 1,755.6 Accounts payable and other current liabilities 83.3 78.5 Current portion of equipment financing obligations 0.1 0.1 Current portion of operating lease liabilities 6.6 6.4 Total stockholders' equity 998.0 1,013.0 • Financial Flexibility to Make Needed Investments to Drive Long ...

Saving lives by improving patient care. 3 rd Quarter 2022 Earnings Results November 8th, 2022 1 2 Forward looking statement This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to r ...

Operations and Services - As of September 30, 2022, NeoGenomics operates CAP accredited and CLIA certified laboratories across multiple locations in the U.S., Europe, and Asia, enhancing its service capabilities[144]. - NeoGenomics is a leading provider of Molecular and NGS testing for oncology, with NGS panels being one of the fastest-growing testing areas, allowing for quicker treatment decisions[148]. - The acquisition of Inivata has expanded NeoGenomics' capabilities in oncology Liquid Biopsy technology, including the InVisionFirst®-Lung assay for non-small cell lung cancer[148]. - The Pharma Services segment supports pharmaceutical firms with comprehensive testing services throughout the drug development process, from discovery to commercialization[152]. - NeoGenomics employs approximately 180 MDs and PhDs, providing a depth of medical expertise that differentiates it from smaller laboratories[161]. - The company aims to maintain industry-leading turnaround times for test results, which is crucial for timely patient treatment[160]. - NeoGenomics focuses on sustainable growth through innovation, aiming to transform patient care and maintain excellence in service and performance[158]. - The company is committed to developing informatics and data-related tools to enhance clinical decision support and patient engagement in precision medicine[155]. - Key focus areas for 2022 include clinical trials and research, validation laboratory services, and informatics[156]. Financial Performance - Consolidated revenues increased by $7.4 million, or 6.1%, year-over-year[172]. - Clinical Services revenue for the three months ended September 30, 2022, increased by $3.9 million, or 3.8%, compared to the same period in 2021[171]. - Pharma Services revenue for the three months ended September 30, 2022, increased by $3.5 million, or 18.3%, compared to the same period in 2021[173]. - Gross profit margin for the three months ended September 30, 2022, was 38.0%, a decrease of 0.9% from 38.9% in the same period of 2021[177]. - General and administrative expenses for the three months ended September 30, 2022, were $64.3 million, an increase of 0.7% from $63.8 million in the same period of 2021[179]. - Cost of revenue for the three months ended September 30, 2022, was $79.9 million, representing 62.0% of total revenue, compared to 61.1% in the same period of 2021[176]. - Loss from operations for the three months ended September 30, 2022, was (30.7)%, an improvement from (32.7)% in the same period of 2021[171]. - Clinical Services cost of revenue for the three months ended September 30, 2022, was $65.3 million, an increase of 9.6% from $59.6 million in the same period of 2021[176]. - Total operating expenses for the three months ended September 30, 2022, were 68.7% of revenue, down from 71.6% in the same period of 2021[171]. - The company reported a net loss of $121.6 million for the nine months ended September 30, 2022, compared to a net income of $33.4 million in the same period in 2021[188]. - Adjusted EBITDA for the nine months ended September 30, 2022, was $(46.8) million, compared to $5.6 million in the same period in 2021[192]. Expenses and Cash Flow - General and administrative expenses increased by $29.5 million for the nine months ended September 30, 2022, compared to the same period in 2021, driven by acquisitions and increased payroll costs[180]. - Research and development expenses rose by $10.3 million for the nine months ended September 30, 2022, primarily due to the Inivata subsidiary, representing a 77.0% increase year-over-year[181]. - Sales and marketing expenses increased by $3.5 million (7.5%) for the nine months ended September 30, 2022, reflecting higher payroll costs from the expansion of the precision medicine sales team[183]. - Cash used in operating activities was $62.3 million for the nine months ended September 30, 2022, a significant increase from $6.9 million in the same period in 2021[194]. - Cash provided by investing activities was $1.6 million for the nine months ended September 30, 2022, a turnaround from $622.8 million used in the same period in 2021[195]. - Cash provided by financing activities decreased significantly to $10.0 million for the nine months ended September 30, 2022, compared to $722.8 million in the same period in 2021, primarily due to the absence of convertible debt or equity offerings[196]. - The end of period cash, cash equivalents, and restricted cash was $266.1 million as of September 30, 2022, down from $343.7 million at the end of the same period in 2021[193]. - As of September 30, 2022, the company had $266.1 million in unrestricted cash and cash equivalents and $177.4 million in marketable securities, sufficient to fund operational liquidity needs for at least the next 12 months[197]. - Capital expenditures for the year ending December 31, 2022, are anticipated to be in the range of $30.0 million to $40.0 million, with approximately $26.4 million spent on capital equipment, software, and leasehold improvements during the nine months ended September 30, 2022[199]. Debt and Financial Risks - The company issued $201.3 million in 2025 Convertible Notes with a fixed interest rate of 1.25% and $345.0 million in 2028 Convertible Notes with a fixed interest rate of 0.25%, with no economic interest rate exposure[207]. - The company invests in highly liquid and high-quality U.S. government and other highly credit-rated debt securities, minimizing exposure to interest rate fluctuations[208]. - The company operates in multiple countries, exposing it to foreign currency exchange risks, but does not currently hedge these risks[209]. - The company performed a qualitative assessment of goodwill as of June 30, 2022, indicating potential impairment due to a decline in stock price from $12.15 to $8.15 per share[204]. - The company anticipates an increase in research and development expenditures in future quarters to support innovation projects and new test developments[182].

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial Officer Vishal Sikri - President of our Pharma Services Division, Inivata Shashi Kulkarni - President of Lab Operations and CSO Conference Call Participants Alex Nowak - Craig-Hallam Capital Andrew Brackmann - William Blair David Delahunt - Goldman Sachs Puneet Souda - SVB Securities Andrew Cooper - Raymond James Mark Massaro - B ...

| --- | --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | | August 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

Financial Data and Key Metrics Changes - Revenue increased 3% year-over-year to $125 million [27] - Clinical services revenue increased 4% year-over-year to $106 million [27] - Average revenue per test increased 7% year-over-year to $387 [27] - GAAP gross margin was 35.1%, while adjusted gross margin was 39%, a decline of 450 basis points year-over-year [31] - Adjusted EBITDA loss was $16 million for the quarter, which is a $3 million improvement from Q1 [35] Business Line Data and Key Metrics Changes - Clinical test volume increased 3% sequentially but was down 3% year-over-year [27] - Pharma services bookings were $46 million in Q2, with a backlog of $299 million, up 6% sequentially and 26% year-over-year [28] - Pharma services revenue increased 6% sequentially to $19 million but was down 4% year-over-year [29] - Informatics revenue continues to grow rapidly within pharma services [30] Market Data and Key Metrics Changes - Volume growth continues to be impacted by operational challenges and a market shift from smaller panels to larger offerings [27] - The company is working to upgrade its NGS product offering and improve lab operations [27] Company Strategy and Development Direction - The company is focused on an 18-month performance improvement initiative called Project Catalyst, which encompasses lab optimization, people and capabilities, competitive growth, and insights and analytics [40][42] - The company is pursuing reimbursement for additional cancer types and anticipates filing a second submission for breast cancer in the first half of 2023 [24] - The incoming CEO, Chris Smith, emphasizes the strategic value of combining clinical business with Pharma Services capabilities and Inivata's liquid biopsy technology [54] Management's Comments on Operating Environment and Future Outlook - Management views 2022 as a rebuilding year, focusing on improving product offerings and operational efficiency [36] - The company expects Q3 revenue to be modestly below Q2, with full-year revenue expected to be flat to up modestly year-over-year [37] - Management anticipates improvement in Q4 and plans to reinstate guidance when reporting Q4 earnings in February [38] Other Important Information - The company has made significant leadership changes, including the appointment of Chris Smith as the new CEO [12][15] - The transition to a new lab facility has been completed, which is expected to lead to improvements in service levels and gross margins [33][130] Q&A Session Summary Question: What is impacting clinical testing volumes? - Management indicated that volume decline is primarily due to internal operational service levels and a shift to more comprehensive offerings, rather than solely a COVID-related hangover [68] Question: Can you elaborate on RaDaR's resubmission to MolDX? - The resubmission was prompted by requests for additional information regarding whole exome sequencing data, and management is confident about meeting the criteria for approval [74] Question: What is the status of the pharma services business? - There is a growing backlog, but revenue conversion has been softer due to sample makeup from clinical trials, which the company is actively addressing [85] Question: What is the outlook for NGS contributions? - The company is seeing growth in NGS, but it is not yet at market rates, and they are working on broader panel offerings [86] Question: What are the expectations for profitability exiting 2023? - Management is working towards profitability but is cautious about committing to specific metrics until the new CEO has assessed the business [99]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer William Bonello - Chief Financial Officer Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Director, Investor Relations Shashi Kulkarni - Chief Scientific Officer David Sholehvar - Clinical Division President Conference Call Participants Brian Weinstein - William Blair Matt Sykes - Goldman Sachs Andrew Coope ...